The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 447)
Therapeutic Pipeline Program, 2017
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB, a neuroprotective receptor. We have screened several independent chemical series of a type of chemical compounds, called TrkB PAMs, which can become optimized (improved) to become potential Parkinso...
Researchers: Robert Lutjens, PhD
Target Advancement Awards, 2017
Parkinson's disease (PD) is characterized by the accumulation of misfolded pathologic alpha-synuclein. This toxic alpha-synuclein moves between neurons and causes progressive neuronal death. Blocking entry of the toxic alpha-synuclein into neurons with an antibody (immune protein) can prevent the progression of neuronal cell death.
Does blocking entry of toxic alpha-sy...
Researchers: Valina L. Dawson, PhD
Research Grant, 2017
Previous research has shown higher levels of the c-Abl protein are activated in the brains of people with Parkinson's disease (PD), and studies have linked c-Abl to pathways associated with the disease. Impeding the activity of this protein could potentially slow or stop the progression of PD, making it an emerging therapeutic target. While much work remains to understand the role ...
Researchers: Tanya Simuni, MD
Research Grant, 2017
Study Rationale & Design:
Components of blood have been found to improve health and enhance multiple biological functions in pre-clinical studies of age-related decline. Blood plasma has been particularly important in regulating the complex mechanisms that can cause these effects. The efficacy of plasma is being studied in the clinic for multiple indications. Alkahest has identified a proprietary p...
Researchers: Sam Jackson, MD, MBA
Target Validation, 2017
Promising Outcomes of Original Grant:
Although the role of alpha-synuclein, the sticky protein that clumps in the cells of people with Parkinson's disease (PD), is not entirely clear, it is believed to control the release of dopamine at synapses, the points of contact between the neural cells. This requires the assistance of another protein, synapsin III (Syn III). We have previously shown that the...
Researchers: Arianna Bellucci, PhD